Search Results - "Bijou, F."

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network by Soussain, C., Choquet, S., Blonski, M., Leclercq, D., Houillier, C., Rezai, K., Bijou, F., Houot, R., Boyle, E., Gressin, R., Nicolas-Virelizier, E., Barrie, M., Moluçon-Chabrot, C., Lelez, M.L., Clavert, A., Coisy, S., Leruez, S., Touitou, V., Cassoux, N., Daniau, M., Ertault de la Bretonnière, M., El Yamani, A., Ghesquières, H., Hoang-Xuan, K.

“…Primary central nervous system lymphomas (PCNSLs) are mainly diffuse large B-cell lymphomas (DLBCLs) of the non-germinal centre B-cell subtype, with unmet…”
Get full text

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group by Tchernonog, E., Faurie, P., Coppo, P., Monjanel, H., Bonnet, A., Algarte Génin, M., Mercier, M., Dupuis, J., Bijou, F., Herbaux, C., Delmer, A., Fabiani, B., Besson, C., Le Gouill, S., Gyan, E., Laurent, C., Ghesquieres, H., Cartron, G.

“…Plasmablastic lymphoma (PBL), initially described in 1997 in the oral cavity of HIV positive patients, is now recognized as a distinct aggressive and rare…”
Get full text

A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor by Leroy, L., Lafarge, X., Blouin, L., Bijou, F., Durrieu, F., Olivier, E., Le Moulec, S.

Get full text

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study by Bommier, C, Donzel, M, Rossi, C, Fornecker, L M, Bijou, F, Chauchet, A, Lebras, L, Ysabaert, L, Haioun, C, Bouabdallah, K, Gastinne, T, Morineau, N, Amorim, S, Jardin, F, Abraham, J, Lamy de la Chapelle, T, Gressin, R, Fouillet, L, Fruchart, C, Olivier, G, Morschhauser, F, Cherblanc, F, Belot, A, Le Guyader, S, Monnereau, A, Ghesquieres, H, Thieblemont, C

“…Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited…”
Get full text

Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function by Mohty, M, Drillat, P, Grouin, J-M, Bijou, F, Milpied, N, Chabannon, C

Get full text

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY by Zinzani, P. L., Mayer, J., Trotman, J., Bijou, F., de Oliveira, A. C., Song, Y., Zhang, Q., Merli, M., Bouabdallah, K., Ganly, P. S., Zhang, H., Johnson, R., Garcia‐Sancho, A. M., Pulla, M. Provencio, Trněný, M., Yuen, S., Assouline, S. E., Auer, R., Ivanoa, E., Kim, P., Greenbaum, A., Huang, S., Delarue, R., Flowers, C. R.

Get full text

RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY by Thieblemont, C., Lamy, T., Tani, M., Krzisch, D., Reda, G., Tedeschi, A., Usai, S. V., Guarini, A., Bijou, F., Stathis, A., Anastasia, A., Devizzi, L., Luminari, S., Arcaini, L., Casasnovas, O., Gressin, R., André, M., Houot, R., Bonomini, L., Zucca, E., Conconi, A.

Get full text

REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort by Bommier, C., Donzel, M., Rossi, C., Fornecker, L., Bijou, F., Chauchet, A., Lebras, L., Ysebaert, L., Haioun, C., Bouabdallah, K., Morineau, N., Gastinne, T., Amorim, S., Jardin, F., Abraham, J., Lamy de la Chapelle, T., Gressin, R., Fouillet, L., Fruchart, C., Morschhauser, F., Olivier, G., Cherblanc, F., Belot, A., Le Guyader, S., Monnereau, A., Ghesquières, H., Thieblemont, C.

Get full text

The choice of in-hospital or home administration for plerixafor injection to poor mobilizers has no adverse consequence on subsequent hematopoietic stem cell harvest by Chabannon, C, Bijou, F, Grouin, J-M, Drillat, P, Milpied, N, Mohty, M

Get full text

A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial by Mozas, P., Ammar, R. Ould, Chartier, L., Nastoupil, L., Bachy, E., Bezsera, S. M., Barnes, J., Bijou, F., Goy, A., Zerazhi, H., Cartron, G., Ojeda‐Uribe, M., Choquet, S., Joly, B., Cheminant, M., García‐Sancho, A. Martín, Eradat, H., Gressin, R., Abrisqueta, P., Parcelier, A., Salazar, M. J. Rodríguez, Bonnet, C., Crump, M., López‐Guillermo, A., Morschhauser, F.

Get full text

BRENTUXIMAB‐VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST‐LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL) by Gallamini, A., Schiano de Colella, J., Viotti, J., Bijou, F., Rambaldi, A., Perrot, A., Patti, C., Gastaud, L., Sorasio, R., Debaigt, C., Schiappa, R., Chamorey, E., Viviani, S., Thyss, A.

Get full text

IBRUTINIB ABOVE 79 YEARS OLD FOR CHRONIC LYMPHOCYTIC LEUKEMIA: IMPORTANT TOXICITIES by Calleja, A., Branco, B., Teste, A., Bijou, F., Clavert, A., Brion, A., Laribi, K., Oberic, L., Guieze, R., Michallet, A., Ysebaert, L.

Get full text

OUTCOME OF PATIENTS WITH C‐MYC REARRANGED DIFFUSE LARGE B CELL LYMPHOMA ASSOCIATED OR NOT WITH BCL2 AND/OR BCL6 REARRANGEMENT: A MULTICENTRIC AND RETROSPECTIVE STUDY by Favre, S., Botella‐Garcia, C., Bijou, F., Deau‐Fisher, B., Banos, A., Rispal, P., Saint‐Lézer, A., Fitoussi, O., Lifermann, F., Labouré, G., Dagada, C., Milpied, N., Bouabdallah, K.

Get full text

S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL by Zinzani, P. L., Mayer, J., Auer, R., Bijou, F., de Oliveira, A. C., Flowers, C. R., Merli, M., Bouabdallah, K., Ganly, P. S., Song, Y., Zhang, H., Johnson, R., García-Sancho, A. M, Provencio, M., Trněný, M., Yuen, S., Tilly, H., Kingsley, E., Tuyman, G., Assouline, S. E., Ivanova, E., Kim, P., Huang, J., Delarue, R., Trotman, J.

Get full text

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY by Opat, S., Hu, B., Tedeschi, A., Linton, K. M., McKay, P., Chan, H., Jin, J., Sun, M., Sobieraj-Teague, M., Zinzani, P. L., Coleman, M., Browett, P., Ke, X., Portell, C. A., Thieblemont, C., Ardeshna, K., Bijou, F., Walker, P., Hawkes, E. A., Ho, S.-J., Zhou, K.-S., Co, M., Xu, J., Liang, Z., Anderson, J., Tankersley, C., Huang, J., Trotman, J.

Get full text

P1133: SUB‐CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW‐TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY by Cartron, G., Bachy, E., Tilly, H., Daguindau, N., Pica, G.‐M., Bijou, F., Mounier, C., Clavert, A. M., Damaj, G. L., Slama, B., Casasnovas, O., Houot, R., Bouabdallah, K., Sibon, D., Fitoussi, O., Morineau, N., Herbaux, C., Gastinne, T., Fornecker, L.‐M., Haioun, C., Launay, V., Araujo, C., Benbrahim, O., Sanhes, L., Gressin, R., Gonzalez, H., Morschhauser, F., Xerri, L., Tarte, K., Pranger, D.

Get full text

P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE by Ghesquieres, H., Cherblanc, F., Belot, A., Camus, V., Thokagevistk, K., Bouabdallah, K.‐K., Esnault, C., Fornecker, L.‐M., Micon, S., Bijou, F., Haioun, C., Morineau, N., Ysebaert, L., Damaj, G., Le Gouill, S., Guidez, S., Morschhauser, F., Thiéblemont, C., Chauchet, A., Gressin, R., Jardin, F., Fruchart, C., Labouré, G., Fouillet, L., Lionne‐Huyghe, P., Bonnet, A., Lebras, L., Amorim, S., Leyronnas, C., Olivier, G., Guieze, R., Lamy, T., Launay, V., Drenou, B., Fitoussi, O., Detourmignies, L., Abraham, J., Soussain, C., Lachenal, F., Fogarty, P., Cony‐Makhoul, P., Bernier, A., Le Guyader‐Peyrou, S., Monnereau, A., Boissard, F., Rossi, C.

Get full text

BRENTUXIMAB‐VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST‐LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL) by Gallamini, A., Bijou, F., Viotti, J., Rossi, A., Perrot, A., Patti, C., Gastaud, L., Sorasio, R., Debaigt, C., Chamorey, E., Viviani, S., Thyss, A.

Get full text

A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B‐CELL LYMPHOMA by Morschhauser, F., Le Gouill, S., Feugier, P., Van Den Neste, E., Nicolas‐Virelizier, E., Bijou, F., Salles, G.A., Tilly, H., Van Eygen, K., Van Hoof, A., Bonnet, C., Haioun, C., Bouabdallah, R., Fabiani, B., Xerri, L., Cartron, G., Houot, R.

Get full text

IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO‐RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END‐POINT OF THE ILOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK by Soussain, C., Choquet, S., Houillier, C., Bijou, F., Houot, R., Boyle, E., Gressin, R., Nicolas‐Virelizier, E., Barrie, M., Moluçon‐Chabrot, C., Lelez, M., Clavert, A., Coisy, S., Bretonnière, M. Ertault, El Yamani, A., Touitou, V., Cassoux, N., Boussetta, S., Broussais, F., Gelas‐Dore, B., Barzic, N., Ghesquières, H., Hoang‐Xuan, K.

Get full text